Orphan Drug PricingOrphan Pricing, Rare-Disease Drug Pricing
The pricing strategies applied to rare disease treatments, frequently priced far higher per patient than common-condition treatments given the smaller patient population.
Pricing & Market Access
Terms for how medicine prices are set and negotiated and how patients gain access to new treatments.
- Topic: Pricing & Market Access
- 40 terms
- Editor reviewed
Outcome-Based PricingPerformance-Based Pricing, Pay-for-Performance Pricing
A pricing arrangement in which some or all payment for a treatment depends on it achieving predefined clinical outcomes in actual practice.
Outcomes-Based ContractValue-Based Contract, Results-Based Agreement
A formal agreement in which some or all of a treatment's payment is contingent on it achieving predefined clinical outcomes in practice.
Patent ExpiryPatent Expiration, Loss of Exclusivity
The date on which a patent's legal protection ends, after which competitors are generally free to market equivalent products without infringement.
Patient Access SchemePAS, Confidential Access Scheme
A managed entry agreement, most associated with the UK, offering a discount to improve a treatment's cost-effectiveness enough to secure reimbursement.
Positive ListReimbursement List, Inclusion List
A list explicitly specifying which medications or services are covered under a health plan, unlike a negative list specifying exclusions.
Price NegotiationPrice Bargaining, Payer-Manufacturer Bargaining
The process through which a manufacturer and payer discuss and agree a drug's price, informed by health economic evidence and negotiating leverage.
Price-Volume AgreementPVA, Volume-Linked Pricing Deal
An arrangement linking a treatment's price to its total utilisation volume, giving payers a mechanism to manage budget exposure as use expands.